+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Steady-state plasma concentrations of mianserin and its major active metabolites, demethylmianserin



Steady-state plasma concentrations of mianserin and its major active metabolites, demethylmianserin



Therapeutic Drug Monitoring 15(2): 113-117



The steady-state plasma concentrations of mianserin and its major active metabolite, desmethylmianserin, were measured in 76 depressed patients receiving 30 mg of mianserin at bedtime. There were considerable interindividual variations in the steady-state plasma concentrations of these compounds; the plasma concentrations of mianserin plus desmethylmianserin were within the therapeutic range suggested previously by us in only 43% of the patients. With advancing age, the plasma concentrations of mianserin increased significantly, while those of mianserin plus desmethylmianserin remained unchanged. Sex, smoking, and coadministration of benzodiazepines did not affect the drug's metabolism. There was no evidence that the kinetics of these compounds were nonlinear with increasing doses. The present study thus suggests that measuring the plasma concentrations of mianserin and desmethylmianserin contributes to rational treatment with this drug, that age, sex, smoking, and coadministration of benzodiazepines are not important factors in determining the dose, and that these compounds have linear kinetics.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009455120

Download citation: RISBibTeXText

PMID: 8503138


Related references

Prediction of plasma concentrations of mianserin and demethylmianserin at steady state from those after an initial dose of mianserin. Therapeutic Drug Monitoring 15(2): 118-121, 1993

Steady-State Plasma Concentrations of Mianserin and Its Major Active Metabolite, Desmethylmianserin. Therapeutic Drug Monitoring 15(2): 113-117, 1993

Subjective side effects of mianserin in relation to plasma concentrations of mianserin and demethylmianserin. Therapeutic Drug Monitoring 14(3): 190-193, 1992

Prediction of Plasma Concentrations of Mianserin and Desmethylmianserin at Steady State from Those After an Initial Dose of Mianserin. Therapeutic Drug Monitoring 15(2): 118-121, 1993

Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 7(5): 369-374, 1997

CYP2D6 genotypes in association with steady state plasma concentrations of active metabolites of tamoxifen in patients with breast cancer. Journal of Clinical Oncology 24(18_Suppl): 634-634, 2016

Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients. European Journal Of Clinical Pharmacology. 53(5): 347-349,., 1998

Plasma concentrations of mianserin after single dose and at steady-state in depressed elderly patients. Clinical Pharmacokinetics 12(1): 73-78, 1987

Is there a therapeutic window for plasma concentration of mianserin plus demethylmianserin. Human Psychopharmacology 6(3): 243-248, 1991

Steady-state plasma concentrations of cis- and trans-10-OH amitriptyline metabolites. Clinical Pharmacology and Therapeutics 31(5): 609-616, 1982

Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clinical Pharmacology and Therapeutics 32(2): 208-211, 1982

The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites. British Journal of Clinical Pharmacology 29(6): 763-765, 1990

Steady-state plasma concentrations of diltiazem and its metabolites in patients and healthy volunteers. Therapeutic Drug Monitoring 18(1): 40-45, 1996

Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. European Journal of Clinical Pharmacology 31(4): 449-455, 1986

Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Clinical Pharmacokinetics 20(3): 237-246, 1991